Latest News - GenSight Biologics

Wednesday, June 14, 2017 | Clinical Trials, GenSight Biologics

GenSight Biologics Reports Long-Term Results in Phase 1/2 Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics reported additional promising clinical trial results with GS010 after 96 weeks of follow-up in its phase 1/2 study. These results confirm the long-term positive sustained visual acu…

Read the full story